الفهرس 
Long-Term Follow-Up Of chronic Hcv Compensated Cirrhotic Egyptian Patients After Treatment With Sofosbuvir Based Regimens
AbstractOnly 14 pages are availabe for public view
 |  | from | 120 |  |  |
| | | from | 120 | | |
Abstract
Hepatitis C virus (HCV) is a major public health problem in Egypt. Direct-Acting Antivirals (DAAs) are considered the ideal choice for the treatment of chronic HCV patients due to their proven efficacy (SVR> 90%) and minimal adverse effects. There is still controversial data regarding the association between DAAs and HCC development.
Aim of work: assessment of long-term follow up effect of different Sofosbuvir-based INF-free DAAs on chronic HCV compensated cirrhotic patients.
Patient and methods: the study was conducted on 424 chronic HCV compensated cirrhotic patients who were candidates for anti-viral therapy according to the guidelines of (NCCVH). Our patients underwent baseline and follow up labs and abdominal ultrasound for a median duration of 200 weeks.
Results: Significant improvement of transaminases, albumin, AFP with P-value <0.01 and a decrease in hemoglobin levels with P-value <0.01 on follow up. Improvement of degree of liver fibrosis was detected by decline in FIB-4 score in 94 patients. There were 39 patients (9.2%) who developed HCC during follow up visits. All patients who developed HCC had low albumin levels.
Conclusion: DAA treatment was not associated with deterioration of biochemical profile, on the contrary, a significant improvement of fibrosis was noticed. However, development of HCC in cirrhotic patients after treatment with DAAs was significant raising the need of close follow up and screening for HCC after treatment